| 0.8967 0.018 (2.01%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.87  |
1-year : | 2.44 |
| Resists | First : | 1.6 |
Second : | 2.08 |
| Pivot price | 0.97 |
|||
| Supports | First : | 0.82 | Second : | 0.68 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 1.09 |
| MA(100) : | 1.94 |
MA(250) : | 3.69 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 13.6 |
| RSI | RSI(14): 25.9 |
|||
| 52-week | High : | 6.88 | Low : | 0.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CMPX ] has closed above bottom band by 26.9%. Bollinger Bands are 43.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.91 - 0.91 | 0.91 - 0.91 |
| Low: | 0.85 - 0.85 | 0.85 - 0.85 |
| Close: | 0.89 - 0.9 | 0.9 - 0.9 |
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Thu, 15 Oct 2026
Compass Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | CMPX | US20454B1044 - www.marketscreener.com
Tue, 13 Oct 2026
Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns - Yahoo Finance
Sun, 11 Oct 2026
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fri, 02 Oct 2026
At $0.92 a share, Compass Therapeutics (CMPX) accounting chief buys 20,000 shares. - Stock Titan
Fri, 25 Sep 2026
After buying 2,500 shares, Compass Therapeutics (CMPX) accounting chief reports a 400,000-share position - Stock Titan
Wed, 23 Sep 2026
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 180 (M) |
| Shares Float | 132 (M) |
| Held by Insiders | 12.4 (%) |
| Held by Institutions | 88.5 (%) |
| Shares Short | 40,360 (K) |
| Shares Short P.Month | 40,790 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.1 % |
| Return on Equity (ttm) | -56.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -2.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|